LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a

Hong-tao Liu, Lei Fang, Yu-xia Cheng & Qing Sun

Department of Pathology, Qian-fo-shan Hospital Affiliated to Shandong University, No. 16766 Jingshi Road, Jinan, Shandong 250014, China

Abstract

Prostate cancer is the third most common causes of death from cancer in men. Our previous study demonstrated that lncRNA PVT1 was overexpressed and played an oncogenic role in the progression of prostate cancer. However, the molecular mechanism of modulating the prostate cancer tumorigenesis was still unknown. In this study, we aim to investigate the interaction between PVT1 and miR-146a in prostate cancer and reveal the potential mechanism in prostate cancer carcinogenesis. The expression level of miR-146a was assessed by quantitative RT-PCR. The correlation analysis and methylation status analysis was made to confirm the interaction between PVT1 and miR-146a. Biological function analysis was performed through gain-of-function and loss-of-function strategies. Our results showed that miR-146a was downregulated and negatively correlated with PVT1 level in prostate cancer. PVT1 mediated miR-146a expression by inducing the methylation of CpG Island in its promoter. miR-146a overexpression eliminated the effects of PVT1 knockdown on prostate cancer cells. PVT1 regulated prostate cancer cell viability and apoptosis depending on miR-146a. Our study suggested a regulatory relationship between LncRNA PVT1 and miR-146a during the process of the prostate cancer tumorigenesis. PVT1 regulated prostate cancer cell viability and apoptosis depending on miR-146a. It would contribute to the diagnosis, treatment and prognosis of prostate cancer.
and cervical cancer, but as a tumor suppressor in pancreatic cancer and breast cancer [25–29]. A study on glioblastoma reported that high expression of miR-146a could inhibit tumor growth and migration of glioma stem-like cells by downregulating Notch-1 [30]. Overexpression of miR-146a was confirmed to suppress the migration and invasion of gastric cancer cells [31]. Transfection of mir-146a in androgen-independent PC3 cells was markedly reducing cell proliferation, invasion, and metastasis [32]. In castration-resistant prostate cancer, miR-146a suppressed tumor growth and progression by targeting EGFR pathway. However, whether there was interaction relationship between miR-146a and PVT1 in prostate cancer tumor progression was unclear.

In this study, we aim to explore the interaction between lncRNA PVT1 and miR-146a in prostate cancer and reveal the potential mechanism in prostate cancer carcinogenesis. Our results suggested that PVT1 exhibited oncogenic activity through the negative regulation of miRNA-146a by inducing the methylation in its promoter.

**Materials and Methods**

**Patients**

Prostate cancer samples and adjacent noncancerous tissues were obtained from Qian-foshan Hospital Affiliated to Shandong University. The diagnosis of prostate cancer was performed according to World Health Organization criteria. Informed consent for the collection of samples was obtained from all patients and donors. This study protocol was approved by the Medical Ethics Committee of Qian-foshan Hospital Affiliated to Shandong University.

**Cell culture**

The human prostate cancer cell lines LNCaP, PC-3 and DU145 were purchased from the American Type Culture Collection (ATCC). Cultures were maintained at 37°C in an atmosphere of 5% CO₂.

**Cell viability and apoptosis assay**

Cells were seeded into 96-well plates at 2 × 10³ cells/well. Cell viability was evaluated using the MTT Cell Proliferation/Viability Assay kit (Sigma, Germany) according to the guidelines. Experiments were independently repeated three times.

Cells were seeded at a density of 1 × 10⁶ cells/well in six-well plates. Apoptosis was evaluated using an Annexin-V-Fluos and Propidium Iodide (PI) Apoptosis Detection Kit (Sigma, Germany) by fluorescence activated cell sorter (FACS) according to the manufacturer’s protocol. Experiments were independently repeated three times.

**Quantitative RT-PCR and MSP**

Total mRNA was isolated using TRIzol Reagent (Takara, Japan) and reverse transcribed into cDNA using Prime Script RT reagent kit (Takara, Japan) according to the manufacturer’s protocol. Real-time PCR was performed by the SYBR Premix Ex TaqTM II kit (Takara, Japan) on a Stratagene MX3005P system (Agilent, Santa Clara, CA, USA). 5 μL was then subjected to Methylation-specific PCR (MSP) with Power SYBR Green PCR Master Mix (Applied Biosystems, Shanghai, China) according to the manufacturer’s guidelines. GAPDH served as an internal standard. Experimental operation and reaction conditions referred to the description previously [33].

**Cell infection and transfection**

PVT1 siRNA/negative control siRNA and PCDNA3-PVT1/PCDNA3-Ctrl were synthesized from Santa Cruz Biological (Santa Cruz, Paso Robles, CA, USA). miR-146a target vector/empty vector and (LNA-anti-miR-146a)/negative control inhibitor (LNA-Ctrl) were purchased from Exiqon (Copenhagen, Denmark). Cells were grown on six-well plates to confluence and, respectively, transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were harvested 48 h post transfection for qRT-PCR to determine the transfection efficiency.

**Statistical analysis**

Data were presented as mean ± standard deviation (SD). Statistical analysis was performed using SPSS software version 16.0. Comparisons of continuous data were analyzed using the independent t-test between the two groups, whereas categorical data were analyzed by the χ² test. P < 0.05 was considered statistically significant.

**Results**

**Expression level of miR-146a is downregulated and negatively correlated with PVT1 level in prostate cancer**

In our previous study, it has been found that PVT1 was overexpressed in prostate cancer and promoted prostate cancer growth in vivo and in vitro. Due to close association between miR-146a and the risk of various cancers [17–24], we speculated that miR-146a may participate in the progress of prostate cancer. To explore whether miR-146a involved in the tumorigenesis of prostate cancer,
we firstly analyzed the expression pattern of miR-146a in prostate cancer tissues. As shown in Figure 1, the mRNA level of miR-146a was significantly downregulated in prostate cancer tissues ($P < 0.0001$), whereas the PVT1 expression was obviously upregulated ($P < 0.0001$). Linear regression analysis showed that the expression level of miR-146a was negatively correlated with the PVT1 in prostate cancer (Fig. 1C, $R^2 = 0.7291$, $P < 0.0001$).

PVT1 regulates miR-146a expression by inducing the methylation of CpG Island in its promoter

To further investigate the relationship between PVT1 and miR-146a, we evaluated the expression of miR-146a in three prostate cancer cell lines (LNCaP, PC-3 and DU145) transfected with either PCDNA3-PVT1 or si-PVT1. Apparently the expression of PVT1 was increased in cells transfected with PCDNA3-PVT1, but decreased in cells transfected with si-PVT1 (Fig. S1). As shown in Figure 2A, the expression of miR-146a was significantly inhibited in LNCaP, PC-3 and DU145 cells when PVT1 was overexpressed ($P < 0.001$). In contrast, PVT1 silencing markedly promoted miR-146a expression in prostate cancer cells (Fig. 2B, $P < 0.001$). It implied that PVT1 regulated the expression of miR-146a. To explore the mechanism of negative regulation of miR-146a by PVT1, we analyzed the level of three active DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) in prostate cancer cell lines using qRT-PCR when PVT1 was aberrantly expressed. It was found that the expression level of DNMT1, DNMT3a, and DNMT3b were obviously increased when PVT1 was overexpressed (Fig. 2C, $P < 0.001$). And the contrary result was observed when PVT1 was knocked-down (Fig. 2D, $P < 0.001$). These results suggested that PVT1 might participate in the regulation of miR-146a methylation. The methylation inhibitor, aza (5-azacytidine), was used to demethylate the miR-146a promoter. As shown in Figure 2E-G, aza increased the expression of miR-146a in a concentration-dependent manner in prostate cancer cell lines. In addition, MSP analysis provided evidences that PVT1 overexpression promoted the methylation of miR-146a CpG islands (Fig. 2H). Taken together, these finding indicated that in prostate cancer, PVT1 regulated miR-146a expression through inducing the methylation of CpG Island in its promoter.

PVT1 regulates prostate cancer cell growth depending on miR-146a

The significant aberrant expression of miR-146a in prostate cancer tissues and negative regulation relationship with PVT1 suggested possible biological significance in tumorigensis. To investigate the biological roles of PVT1 and miR-146a in prostate cancer, we applied gain-of-function and loss-of-function strategies. Knockdown of miR-146a was evidenced by marked decrease in miR-146a expression while significantly increased miR-146a expression was observed in cells transfected with miR-146a target vector (Fig. S1). It was demonstrated that PVT1 knockdown caused a significant reduction in cell viability and a promotion in cell apoptosis (Fig. 3, $P < 0.001$). Similarly, miR-146a overexpression significantly inhibited cell survival and accelerated cell apoptosis in prostate cancer (Fig. 3, $P < 0.001$). But miR-146a overexpression eliminated the effect of PVT1 knockdown on cell proliferation and apoptosis in prostate cancer cells (Fig. 3). Furthermore, as shown in Figure 4, miR-146a silencing significantly promoted the cell viability, suppressed cell apoptosis. And the antitumor effect of PVT1 knockdown was counteracted when miR-146a was silenced in prostate cancer cells. These results suggested that PVT1 regulated prostate cancer cell viability and apoptosis depending on miR-146a.
Figure 2. PVT1 regulated the expression of miR-146a by inducing the methylation of CpG Island in its promoter. (A–B) miR-146a expression level was down-regulated with PVT1 overexpression and upregulated with PVT1 silencing. The expression level of miR-146a was measured by qRT-PCR in LNCaP, PC-3, and DU145 cells transfected with either pCDNA3-PVT1 or si-PVT1. (C–D) DNMT1, DNMT3a, and DNMT3b expression levels were increased with PVT1 overexpression, and decreased with PVT1 silencing. The level of DNMT1, DNMT3a, and DNMT3b were analyzed using qRT-PCR. (E–G) Methylation inhibitor 5-azacytidine increased the miR-146a expression. The expression level of miR-146a was examined by qRT-PCR in LNCaP, PC-3, and DU145 cells. (H) PVT1 overexpression promoted the methylation of miR-146a CpG islands. The methylation of miR-146a CpG sites was analyzed by Methylation-specific PCR (MSP) analysis in LNCaP, PC-3, and DU145 cells. **P < 0.01

Figure 3. miR-146a overexpression eliminated the effects of PVT1 knockdown on prostate cancer cells. (A–C) miR-146a overexpression eliminated the effect of PVT1 knockdown on cell viability of prostate cancer cells. LNCaP, PC-3, and DU145 cells were transfected with empty vector or miR-146a target vector for 24 h and then infected with si-PVT1. Relative cell numbers were evaluated using MTT analysis at the indicated time points. **P < 0.01 indicates vector+si-Ctrl versus vector+si-PVT1, #P < 0.05, ##P < 0.01 indicate vector+si-Ctrl versus miR-146a+si-Ctrl. (D–F) miR-146a overexpression blocked the effect of PVT1 knockdown on the apoptosis of prostate cancer cells. The percentage of apoptotic cells were analyzed with FACS. n.s., no significance; FACS, fluorescence activated cell sorter.
Discussion

LncRNA PVT1, a powerful predictive factor of tumor progression and patient survival in various cancers, has been demonstrated to play important roles in various biological processes, such as proliferation, apoptosis, mobility, and invasion [8–12]. In our previous study, we confirmed that PVT1 predicted patient prognosis and regulated tumor growth in prostate cancer. However, the underlying molecular mechanism and related target genes were still unclear. In this study, we presented evidences that PVT1 exhibited oncogenic activity through the negative regulation of miRNA-146a. PVT1 mediated the miR-146a expression by inducing the methylation in its promoter.

miR-146a was found to be associated with the risk of various cancers, including gastric cancer, hepatocellular carcinoma, lung cancer, breast and ovarian cancer, bladder cancer, prostate cancer, etc [17–24]. Some researchers have focused on its biological role and association with clinical response. It was found that miR-146a decreased the sensitivity of HCC cells to the cytotoxic effects of IFN-α through the suppression of apoptosis [25]. Overexpression of miR-146a was confirmed to suppress the migration and invasion of gastric cancer cells [31]. Deregression expression of miR-146a affected EGFR signaling in pancreatic cancer model [34]. In this study, it was found that miR-146a was significantly low expression in prostate cancer tissues, suggesting possible biological significance in tumorigenesis of prostate cancer. In addition, the expression level of miR-146a was negatively correlated with the PVT1 expression. It implied that there may be a certain relationship between PVT1 and miR-146a in prostate cancer.

Further research indicated that PVT1 regulated miR-146a expression through the methylation in miR-146a promoter. PVT1 knockdown markedly promoted miR-146a expression, whereas the expression of miR-146a was significantly inhibited in prostate cancer cells transfected with PCDNA3-PVT1. In addition, PVT1 overexpression obviously increased the activity of DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) in prostate cancer cells. MSP analysis also provided evidences that PVT1 overexpression promoted the methylation of miR-146a CpG islands. DNA methylation played an important role
Conflict of Interest

All the authors declare that they have no conflict of interest.

References

1. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9–29.
2. Bilusic, M., C. Heery, and R. A. Madan. 2011. Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. Vaccine 29:6485–6497.
3. Siegel, R., C. DeSantis, K. Virgo, K. Stein, A. Mariotto, T. Smith, et al. 2012. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 62:220–241.
4. Xue, G., Z. Ren, Y. Chen, J. Zhu, Y. Du, D. Pan, et al. 2015. A feedback regulation between mir-145 and DNA methyltransferase 3b in prostate cancer cell and their responses to irradiation. Cancer Lett. 361:121–127.
5. Roehl, K. A., M. Han, C. G. Ramos, J. A. Antenor, and W. J. Catalona 2004. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J. Urol. 172:910–914.
6. Thompson, I., J. B. Thrasher, G. Aus, A. L. Burnett, E. D. Canby-Hagino, M. S. Cookson, et al. 2007. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177:2106–2131.
7. Boorjian, S. A., J. A. Eastham, M. Graefen, B. Guillonneau, R. J. Karnes, J. W. Moul, et al. 2012. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur. Urol. 61:664–675.
8. Zhang, Z., Z. Zhu, B. Zhang, W. Li, X. Li, X. Wu, et al. 2014. Frequent mutation of rs13281615 and its association with pvt1 expression and cell proliferation in breast cancer. J. Genet. Genomics 41:187–195.
9. Y. R. Yang, S. Z. Zang, C. L. Zhong, Y. X. Li, S. S. Zhao, and X. J. Feng. 2014. Increased expression of the lncrna pvt1 promotes tumorigenesis in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 7:6929–6935.
10. Ding, C., Z. Yang, Z. Lv, C. Du, H. Xiao, C. Peng, et al. 2015. Long non-coding rna pvt1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncol. Lett. 9:955–963.
11. Ding, J., D. Li, M. Gong, J. Wang, X. Huang, T. Wu, et al. 2014. Expression and clinical significance of the long non-coding rna pvt1 in human gastric cancer. OncoTargets Ther. 7:1625–1630.
12. Takahashi, Y., G. Sawada, J. Kurashige, R. Uchi, T. Matsumura, H. Ueo, et al. 2014. Amplification of pvt-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br. J. Cancer 110:164–171.
Role of PVT1 in Prostate Cancer

13. Fang, X. Y., H. F. Pan, R. X. Leng, and D. Q. Ye. 2015. Long noncoding rnas: Novel insights into gastric cancer. Cancer Lett. 356:357–366.

14. Guan, Y., W. L. Kuo, J. L. Stilwell, H. Takano, A. V. Lapuk, J. Fridlyand, et al. 2007. Amplification of pvt1 contributes to the pathophysiology of ovarian and breast cancer. Clin. Cancer Res. 13:5745–5755.

15. Soubra, A., B. Koney, and A. Bagchi. 2015. Mp61-06 increased pvt1 expression correlates with advanced stage and hormone resistance of prostate cancer. J. Urol. 193:e748–e749.

16. Meyer, K. B., A. T. Maia, M. O’Reilly, M. Ghoussaini, R. Prathalingam, P. Porter-Gill, et al. 2011. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with pvt1 expression. PLoS Genet. 7:e1002165.

17. Fu, B., P. Song, M. Lu, B. Wang, and Q. Zhao. 2014. The association between mir-146a gene rs2910164 polymorphism and gastric cancer risk: A meta-analysis. Biomed. Pharmacother. 68:923–928.

18. Xu, T., Y. Zhu, Q. K. Wei, Y. Yuan, F. Zhou, Y. Y. Ge, et al. 2008. A functional polymorphism in the mir-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 29:2126–2131.

19. Jeon, H. S., Y. H. Lee, S. Y. Lee, J. A. Jang, Y. Y. Choi, S. S. Yoo, et al. 2014. A common polymorphism in pre-microrna-146a is associated with lung cancer risk in a korean population. Gene 534:66–71.

20. Pastrello, C., J. Polese, L. Della Puppa, A. Viel, and R. Maestro. 2010. Association between hsa-mir-146a genotype and tumor age-of-onset in brcal/brca2-negative familial breast and ovarian cancer patients. Carcinogenesis 31:2124–2126.

21. Mittal, R. D., R. Gangwar, G. P. George, T. Mittal, and R. Kapoor. 2011. Investigative role of pre-micrornas in bladder cancer patients: A case–control study in north india. DNA Cell Biol. 30:401–406.

22. Xu, B., N. H. Feng, P. C. Li, J. Tao, D. Wu, Z. D. Zhang, et al. 2010. A functional polymorphism in pre-mir-146a gene is associated with prostate cancer risk and mature mir-146a expression in vivo. Prostate 70:467–472.

23. George, G. P., R. Gangwar, R. K. Mandal, S. N. Sankhwar, and R. D. Mittal. 2011. Genetic variation in microrna genes and prostate cancer risk in north indian population. Mol. Biol. Rep. 38:1609–1615.

24. Nikić, Z. Z., D. L. S. Pavicic, V. D. Vukotić, S. M. Tomović, S. J. Cerović, N. Filipović, et al. 2014. Association between genetic variation in hsa-mir-146a gene and prostate cancer progression: Evidence from serbian population. Cancer Causes Control 25:1571–1575.

25. Tomokuni, A., H. Eguchi, Y. Tomimaru, et al. 2011. Mir-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 414:675–680.

26. Wang, X., S. Tang, S. Y. Le, R. Lu, J. S. Rader, C. Meyers, and Z. M. Zheng. 2008. Aberrant expression of oncogenic and tumor-suppressive micrornas in cervical cancer is required for cancer cell growth. PLoS ONE 3:e2557.

27. Bhauvik, D., G. Scott, S. Schokrur, C. K. Patil, J. Campisi, and C. C. Benz. 2008. Expression of microrna-146 suppresses nf-kb activity with reduction of metastatic potential in breast cancer cells. Oncogene 27:5643–5647.

28. Hurst, D. R., M. D. Edmonds, G. K. Scott, C. C. Benz, K. S. Vaidya, and D. R. Welch. 2009. Breast cancer metastasis suppressor 1 up-regulates mir-146, which suppresses breast cancer metastasis. Cancer Res. 69:1279–1283.

29. Li, Y., T. G. VandenBoom, Z. Wang, D. Kong, S. Ali, P. A. Philip, et al. 2010. Mir-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70:1486–1495.

30. Mei, J., R. Bachoo, and C. L. Zhang. 2011. Microrna-146a inhibits glioma development by targeting notch1. Mol. Cell. Biol. 31:3584–3592.

31. Yao, Q., Z. Cao, C. Tu, Y. Zhao, H. Liu, and S. Zhang. 2013. Microrna-146a acts as a metastasis suppressor in gastric cancer by targeting wasf2. Cancer Lett. 335:219–224.

32. Lin, S. L., A. Chiang, D. Chang, and S. Y. Ying. 2008. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14:417–424.

33. Hanoun, N., Y. Delpu, A. A. Suriawinata, B. Bournet, C. Bureau, J. Selves, et al. 2010. The silencing of microrna 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin. Chem. 56:1107–1118.

34. Ali, S., A. Ahmad, A. Aboukameel, A. Ahmed, B. Bao, S. Banerjee, et al. 2014. Deregalation of mir-146a expression in a mouse model of pancreatic cancer affecting egfr signaling. Cancer Lett. 351:134–142.

35. Lyko, F., and R. Brown. 2005. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. Natl Cancer Inst. 97:1498–1506.

36. Hu, C., and J. Zhou. 2009. Abnormality of DNA methylation modification and lung cancer. International Journal of Pathology and Clinical Medicine 5:398–402.

37. Beck-Engeser, G. B., A. M. Lum, K. Huppi, N. J. Caplen, B. B. Wang, and M. Wabl. 2008. Pvt1-encoded micrornas in oncogenesis. Retrovirology 5:4.

38. Alvarez, M. L., M. K罗斯heidiari, E. Eddy, and J. Kiefer. 2013. Role of microrna 1207-5p and its host gene, the long non-coding rna pvt1, as mediators of extracellular matrix accumulation in the kidney: Implications for diabetic nephropathy. PLoS ONE 8:e77468.

39. Zhang, X. W., P. Bu, L. Liu, X. Z. Zhang, and J. Li. 2015. Overexpression of long non-coding rna pvt1 in gastric cancer cells promotes the development of...
multidrug resistance. Biochem. Biophys. Res. Commun. 462:227–232.

**Supporting Information**

Additional supporting information may be found in the online version of this article:

**Figure S1.** Relative expression level of PVT1 and miR-146a. (A–C) Relative expression level of PVT1 in LNCaP, PC-3 and DU145 cells when PVT1 was overexpressed or knocked-down. (D–F) Relative expression level of miR-146a in LNCaP, PC-3, and DU145 cells when miR-146a was overexpressed or silenced. **P < 0.01 versus Ctrl.**